NCT06110195 - Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Head and Neck CancerHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Xevinapant

Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.

DRUG

Carboplatin

Given with radiation weekly for 7 doses.

DRUG

Paclitaxel

Given with radiation weekly for 7 doses.

RADIATION

Radiation Therapy

Radiation will be given together with paclitaxel and carboplatin for 7 weeks.

Trial Locations (1)

60637

University of Chicago Medicine Comprehensive Cancer Center, Chicago